## AMENDMENTS TO AND LISTING OF CLAIMS

## 1. (Currently amended) A compound of formula I

$$R_5R_4N$$
  $R_1$   $R_2$ 

wherein

R<sub>1</sub> is C<sub>1-6</sub>-alkyl optionally substituted by OH, C<sub>1-2</sub>-alkoxy or 1-to-6 fluorine atoms; C<sub>2-6</sub>-alkenyl; or C<sub>2-6</sub>-alkynyl;

R<sub>2</sub> is a radical of formula a or b

wherein

- R<sub>6</sub> is C<sub>1-12</sub>-alkyl optionally substituted by halogen, by an optionally-substituted cycloalkyl, by an optionally-substituted phenyl, by an optionally-substituted heteroaryl, or by an optionally-substituted heterocyclic residue, wherein the C<sub>1-12</sub>-alkyl optionally is interrupted by one or more O or C=O; and wherein the phenyl, heteroaryl, cycloalkyl, and/or heterocyclic residue may be substituted by 1-to-5 substituents independently selected from hydroxy; halogen; C<sub>1-4</sub>-alkyl; C<sub>1-4</sub>-alkyl substituted by 1-to-5 fluorine atoms; C<sub>1-4</sub>-alkoxy; C<sub>1-4</sub>-alkoxy substituted by 1-to-5 fluorine atoms; cyano; phenyl; and phenyl substituted by 1-to-5 substituents independently selected from hydroxy, halogen, C<sub>1-4</sub>-alkyl, C<sub>1-4</sub>-alkoxy, and cyano;
- R<sub>7</sub> is H, optionally-substituted phenyl, optionally-substituted heteroaryl, where<u>in</u> the phenyl and/or heteroaryl, independently, may be substituted by 1-to-5 substituents independently selected from hydroxy; halogen; C<sub>1-4</sub>-alkyl; C<sub>1-4</sub>-alkyl substituted by 1-to-5 fluorine atoms; C<sub>1-4</sub>-alkoxy; C<sub>1-4</sub>-alkoxy substituted by 1-to-5 fluorine atoms; and cyano; <u>and</u>

X is O;

Z is N or O:

- R<sub>3</sub> is -A-B-COOH, where each of A and B, independently, is a bond, C=O or CDE, wherein each of D and E, independently, is H, halogen, C<sub>1-3</sub>-alkyl or OH; with the proviso that A and B are not both C=O; and
- each of R<sub>4</sub> and R<sub>5</sub>, independently, is H, C<sub>1-4</sub>-alkyl optionally substituted by 1, 2 or 3 halogen atoms, or acyl, where acyl is a residue W-CO, wherein W is C<sub>1-6</sub>-alkyl, C<sub>3-6</sub>-cycloalkyl, phenyl or phenylC<sub>1-4</sub>-alkyl;

with the proviso that when  $R_4$  is H,  $R_5$  is H,  $R_3$  is COOH,  $R_2$  is a radical of formula a and  $R_7$  is H, and either i)  $R_1$  is  $CH_2OH$  and  $XR_6$  is an unsubstituted  $C_{1-12}$ -alkyl that is not para to  $(CH_2)_2$ - $CR_1R_3(NR_4R_5)$ ; or ii)  $R_1$  is  $CH_3$  and  $XR_6$  is an unsubstituted  $OC_{1-12}$ -alkyl that is not meta to  $(CH_2)_2$ - $CR_1R_3(NR_4R_5)$ ;

where heteroaryl is pyridyl, pyrimidinyl, pyrazinyl, furyl, oxazolyl, isoxazolyl, thiophenyl, thialzolyl, isothiazolyl, pyrrolyl, imidazolyl or pyrazolyl; cycloalkyl is C<sub>3-6</sub>-cycloalkyl; and a heterocyclic residue is tetrahydrofuryl, tetrahydropyranyl, aziridinyl, piperidinyl, pyrrolidinyl or piperazinyl; in free form or in salt form.

2. (Currently amended) A compound of formula II

$$R_6R'_4N$$
  $R_1$   $R_2$ 

Ш

wherein  $R_1$ ,  $R_2$ ,  $R_3$  and  $R_5$  are as defined in Claim 1, and  $R_4$  is a protecting group selected from benzyl, p-methoxybenzyl, methoxymethyl, tetrahydropyranyl, trialkylsilyl, acyl, where acyl is a residue W-CO, wherein W is  $C_{1-6}$ -alkyl,  $C_{3-6}$ -cycloalkyl, phenyl or phenyl $C_{1-4}$ -alkyl, tert-butoxycarbonyl, benzyloxycarbonyl, 9-fluorenylmethoxycarbonyl and trifluoroacetyl, or a salt thereof.

- 3. (Previously presented) A compound according to Claim 1 which is selected from (R)-3-amino-5-(4-heptyloxy-phenyl)-3-methyl-pentanoic acid, (R)-4-amino-6-(4-heptyloxy-phenyl)-4-methyl-hexanoic acid and (R)-2-amino-4-(4-heptyloxy-phenyl)-2-methyl-butanoic acid.
- 4. (Previously presented) A pharmaceutical composition comprising a compound according to Claim 1 in free form or in a pharmaceutically-acceptable salt form, together with one or more pharmaceutically-acceptable diluents or carriers therefor.
- 5-16 (Canceled)
- 17. (Currently amended) The pharmaceutical combination composition of Claim 7 4, wherein the compound is of formula II

$$R_5R'_4N$$
 $R_1$ 
 $R_2$ 

wherein  $R_1$ ,  $R_2$ ,  $R_3$  and  $R_5$  are as defined are as defined in Claim 1, and  $R_4$  is a

protecting group, or a salt thereof.

18. (Currently amended) The pharmaceutical eembination composition of Claim 7 4, wherein the compound is selected from (R)-3-amino-5-(4-heptyloxy-phenyl)-3-methyl-pentanoic acid, (R)-4-amino-6-(4-heptyloxy-phenyl)-4-methyl-hexanoic acid and (R)-2-amino-4-(4-heptyloxy-phenyl)-2-methyl-butanoic acid.